Last reviewed · How we verify
M-CENK
M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis.
M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis. Used for Metastatic solid tumors.
At a glance
| Generic name | M-CENK |
|---|---|
| Also known as | Autologous Memory Cytokine Enriched Natural Killer |
| Sponsor | ImmunityBio, Inc. |
| Drug class | Checkpoint inhibitor |
| Target | CD47 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
M-CENK works by blocking the CD47/SIRPα axis, which is a checkpoint that cancer cells use to evade the immune system. By blocking this axis, M-CENK allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Metastatic solid tumors
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (PHASE2)
- Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. (PHASE2)
- Immunotherapy Before and After Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M-CENK CI brief — competitive landscape report
- M-CENK updates RSS · CI watch RSS
- ImmunityBio, Inc. portfolio CI